Time to progression can also be predicted by cell-surface IgM levels prior to ibrutinib treatment, suggesting another non-genetic mechanism of ibrutinib resistance in CLL, potentially similar to the CD79B overexpression in DLBCL (Figure 1) (152, 156). This evidence concerns the gene CD40LG and B-cell chronic lymphocytic leukemia.